|
Quince Therapeutics, Inc. (QNCX) Évaluation DCF |
Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
Pré-Construits Pour Une Utilisation Rapide Et Efficace
Compatible MAC/PC, entièrement débloqué
Aucune Expertise N'Est Requise; Facile À Suivre
Quince Therapeutics, Inc. (QNCX) Bundle
En tant qu'investisseur ou analyste, cette calculatrice [symbole] DCF est votre ressource incontournable pour une évaluation précise. Chargé de données réelles de Quince Therapeutics, Inc. (QNCX), vous pouvez ajuster les prévisions et observer immédiatement les effets.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -78.6 | -90.0 | -52.0 | -31.3 | -57.3 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Depreciation | .3 | .3 | .2 | .3 | .0 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| EBIT | -78.9 | -90.3 | -52.2 | -31.6 | -57.3 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Total Cash | 133.8 | 106.8 | 90.2 | 75.1 | 40.8 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | 1.0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Inventories | .0 | 2.2 | 2.3 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Accounts Payable | 3.6 | 4.9 | .6 | 2.0 | 2.9 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | -.1 | -.2 | -.1 | -.2 | -.3 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
| Tax Rate, % | -0.15333 | -0.15333 | -0.15333 | -0.15333 | -0.15333 | -0.15333 | -0.15333 | -0.15333 | -0.15333 | -0.15333 |
| EBITAT | -78.9 | -89.7 | -51.9 | -31.4 | -57.4 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -75.1 | -90.4 | -56.2 | -28.5 | -55.8 | -2.9 | .0 | .0 | .0 | .0 |
| WACC, % | 6.75 | 6.74 | 6.75 | 6.75 | 6.75 | 6.75 | 6.75 | 6.75 | 6.75 | 6.75 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -2.7 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -3 | |||||||||
| Net Debt | 9 | |||||||||
| Equity Value | -11 | |||||||||
| Diluted Shares Outstanding, MM | 43 | |||||||||
| Equity Value Per Share | -0.26 |
What You Will Receive
- Comprehensive Financial Model: Quince Therapeutics' actual data facilitates accurate DCF valuation.
- Complete Forecast Flexibility: Modify revenue growth, profit margins, discount rates, and other essential factors.
- Real-Time Calculations: Automatic updates provide immediate results as adjustments are made.
- Professional-Grade Template: A polished Excel file crafted for high-quality valuation.
- Adaptable and Reusable: Designed for versatility, enabling repeated application for in-depth forecasts.
Key Features
- Comprehensive Data: Quince Therapeutics’ historical financial statements and pre-filled projections.
- Customizable Inputs: Modify WACC, tax rates, revenue growth, and EBITDA margins as needed.
- Real-Time Insights: Observe Quince Therapeutics’ intrinsic value update instantly.
- Intuitive Visual Outputs: Dashboard graphs illustrate valuation results and essential metrics.
- Designed for Precision: A professional-grade tool for analysts, investors, and finance professionals.
How It Works
- Download the Template: Gain immediate access to the Excel-based QNCX DCF Calculator.
- Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and other variables.
- Instant Calculations: The model automatically recalculates Quince Therapeutics’ intrinsic value.
- Test Scenarios: Experiment with various assumptions to assess potential changes in valuation.
- Analyze and Decide: Utilize the results to inform your investment or financial decisions.
Why Choose This Calculator?
- User-Friendly Interface: Perfect for both novice and experienced users.
- Customizable Inputs: Tailor assumptions to suit your specific analysis needs.
- Real-Time Feedback: Observe immediate updates to Quince Therapeutics’ valuation as you adjust the parameters.
- Preloaded Data: Comes with Quince Therapeutics’ actual financial information for swift evaluations.
- Relied Upon by Experts: A go-to tool for investors and analysts for making educated choices.
Who Should Use Quince Therapeutics, Inc. (QNCX)?
- Healthcare Investors: Make informed decisions with a reliable analysis of therapeutic innovations.
- Biotech Analysts: Streamline your research with comprehensive data on drug development and market potential.
- Consultants: Efficiently modify reports and presentations tailored to client needs in the biotech sector.
- Medical Professionals: Enhance your knowledge of cutting-edge therapies and their implications for patient care.
- Students and Educators: Utilize as a resource for understanding biotechnology and pharmaceutical industry dynamics.
What the Template Contains
- Historical Data: Includes Quince Therapeutics’ past financials and baseline forecasts.
- DCF and Levered DCF Models: Detailed templates to calculate Quince Therapeutics’ intrinsic value.
- WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
- Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: A complete breakdown of Quince Therapeutics’ financials.
- Interactive Dashboard: Visualize valuation results and projections dynamically.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.